# Liraglutide en gewicht bij gevorderd HFrEF: FIGHT-trial inzichten

*geplaatst 2018-12-01 · Hartfalen · ESC heart failure · doi 10.1002/ehf2.12334 · https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/*

FIGHT-trial analyse naar gewichtseffecten van liraglutide bij gevorderd HFrEF. Geen voordelig gewichtsverlies in deze populatie.

## English: Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.

This FIGHT trial analysis showed that liraglutide does not produce beneficial weight loss in patients with advanced HFrEF, suggesting that the GLP-1 receptor agonist weight loss mechanism is attenuated in the sickest heart failure patients.

## Abstract (original, from the publication)

AIMS: Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with HF and reduced ejection fraction (HFrEF) and a recent acute HF hospitalization remains unknown. METHODS AND RESULTS: The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo. The primary outcome for this post hoc analysis was the change in weight from baseline to last study visit. We conducted an 'on-treatment' analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo). The median age was 61 years, 21% were female, and 69% of patients had New York Heart Association functional Class III or IV symptoms. The median ejection fraction was 25% (25th, 75th percentile 19-32%). Liraglutide use was associated with a significant weight reduction [liraglutide -1.00 lbs vs. placebo 2.00 lbs; treatment difference -4.10 lbs; 95% confidence interval (CI) -7.94, -0.25; P = 0.0367; percentage treatment difference -2.07%, 95% CI -3.86, -0.28; P = 0.0237]. Similar results were seen after multivariable adjustments. Liraglutide also significantly reduced triglyceride levels (liraglutide 7.5 mg/dL vs. placebo 12.0 mg/dL; treatment difference -33.1 mg/dL; 95% CI -60.7, -5.6; P = 0.019). CONCLUSIONS: Liraglutide is an efficacious weight loss agent in patients with HFrEF. These findings will require further exploration in a well-powered cardiovascular outcomes trial.

Auteurs: Abhinav Sharma, Andrew P Ambrosy, Adam D DeVore, Kenneth B Margulies, Steven E McNulty, Robert J Mentz, Adrian F Hernandez, Gary Michael Felker, Lauren B Cooper, Anuradha Lala, Justin Vader, John D Groake, Barry A Borlaug, Eric J Velazquez

---
Bron: ESC heart failure, https://doi.org/10.1002/ehf2.12334. Bijgewerkt 2026-07-03T13:26:51Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.